270 related articles for article (PubMed ID: 9400001)
1. L-745,870, a subtype selective dopamine D4 receptor antagonist, does not exhibit a neuroleptic-like profile in rodent behavioral tests.
Bristow LJ; Collinson N; Cook GP; Curtis N; Freedman SB; Kulagowski JJ; Leeson PD; Patel S; Ragan CI; Ridgill M; Saywell KL; Tricklebank MD
J Pharmacol Exp Ther; 1997 Dec; 283(3):1256-63. PubMed ID: 9400001
[TBL] [Abstract][Full Text] [Related]
2. CI-943, a potential antipsychotic agent. I. Preclinical behavioral effects.
Heffner TG; Downs DA; Meltzer LT; Wiley JN; Williams AE
J Pharmacol Exp Ther; 1989 Oct; 251(1):105-12. PubMed ID: 2571712
[TBL] [Abstract][Full Text] [Related]
3. Ziprasidone (CP-88,059): a new antipsychotic with combined dopamine and serotonin receptor antagonist activity.
Seeger TF; Seymour PA; Schmidt AW; Zorn SH; Schulz DW; Lebel LA; McLean S; Guanowsky V; Howard HR; Lowe JA
J Pharmacol Exp Ther; 1995 Oct; 275(1):101-13. PubMed ID: 7562537
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological profile of SCH39166: a dopamine D1 selective benzonaphthazepine with potential antipsychotic activity.
Chipkin RE; Iorio LC; Coffin VL; McQuade RD; Berger JG; Barnett A
J Pharmacol Exp Ther; 1988 Dec; 247(3):1093-102. PubMed ID: 2905002
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological characterization of PD 118717, a putative piperazinyl benzopyranone dopamine autoreceptor agonist.
Pugsley TA; Christofferson CL; Corbin A; DeWald HA; Demattos S; Meltzer LT; Myers SL; Shih YH; Whetzel SZ; Wiley JN
J Pharmacol Exp Ther; 1992 Dec; 263(3):1147-58. PubMed ID: 1361570
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological profile of the new potent neuroleptic ocaperidone (R 79,598).
Megens AA; Awouters FH; Meert TF; Schellekens KH; Niemegeers CJ; Janssen PA
J Pharmacol Exp Ther; 1992 Jan; 260(1):146-59. PubMed ID: 1370538
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties.
Oka M; Noda Y; Ochi Y; Furukawa K; Une T; Kurumiya S; Hino K; Karasawa T
J Pharmacol Exp Ther; 1993 Jan; 264(1):158-65. PubMed ID: 8093723
[TBL] [Abstract][Full Text] [Related]
8. DuP 734 [1-(cyclopropylmethyl)-4-(2'(4''-fluorophenyl)-2'- oxoethyl)piperidine HBr], a potential antipsychotic agent: preclinical behavioral effects.
Cook L; Tam SW; Rohrbach KW
J Pharmacol Exp Ther; 1992 Dec; 263(3):1159-66. PubMed ID: 1361571
[TBL] [Abstract][Full Text] [Related]
9. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties.
Janssen PA; Niemegeers CJ; Awouters F; Schellekens KH; Megens AA; Meert TF
J Pharmacol Exp Ther; 1988 Feb; 244(2):685-93. PubMed ID: 2450200
[TBL] [Abstract][Full Text] [Related]
10. CI-1007, a dopamine partial agonist and potential antipsychotic agent. II. Neurophysiological and behavioral effects.
Meltzer LT; Christoffersen CL; Corbin AE; Ninteman FW; Serpa KA; Wiley JN; Wise LD; Heffner TG
J Pharmacol Exp Ther; 1995 Aug; 274(2):912-20. PubMed ID: 7636754
[TBL] [Abstract][Full Text] [Related]
11. Neuropsychopharmacological profile in rodents of SR 57746A, a new, potent 5-HT1A receptor agonist.
Simiand J; Keane PE; Barnouin MC; Keane M; Soubrié P; Le Fur G
Fundam Clin Pharmacol; 1993; 7(8):413-27. PubMed ID: 7904976
[TBL] [Abstract][Full Text] [Related]
12. Partial dopamine-agonistic and atypical neuroleptic properties of the amino-ergolines SDZ 208-911 and SDZ 208-912.
Coward DM; Dixon AK; Urwyler S; White TG; Enz A; Karobath M; Shearman G
J Pharmacol Exp Ther; 1990 Jan; 252(1):279-85. PubMed ID: 1967646
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent.
Szewczak MR; Corbett R; Rush DK; Wilmot CA; Conway PG; Strupczewski JT; Cornfeldt M
J Pharmacol Exp Ther; 1995 Sep; 274(3):1404-13. PubMed ID: 7562515
[TBL] [Abstract][Full Text] [Related]
14. Substituted ergolines: potential antipsychotics with unique profile. I. Psychopharmacological characterization.
Groó D; Palosi A
Pol J Pharmacol Pharm; 1988; 40(6):593-601. PubMed ID: 2908363
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological studies with two new ergoline derivatives, the potential antipsychotics LEK-8829 and LEK-8841.
Krisch I; Bole-Vunduk B; Pepelnak M; Lavric B; Ocvirk A; Budihna MV; Sket D
J Pharmacol Exp Ther; 1994 Oct; 271(1):343-52. PubMed ID: 7965734
[TBL] [Abstract][Full Text] [Related]
16. Is dopamine antagonism a requisite of neuroleptic activity?
Greenblatt EN; Coupet J; Rauh E; Szucs-Myers VA
Arch Int Pharmacodyn Ther; 1980 Nov; 248(1):105-19. PubMed ID: 6111298
[TBL] [Abstract][Full Text] [Related]
17. In the search for a novel class of antipsychotic drugs: preclinical pharmacology of FG5803, a 1-piperazinecarboxamide derivative.
Björk A; Christensson E; Albinsson A; Gustafsson B; Pettersson E; Pettersson G; Svartengren J; Andersson G
J Pharmacol Exp Ther; 1994 Dec; 271(3):1338-47. PubMed ID: 7996444
[TBL] [Abstract][Full Text] [Related]
18. Effects of yohimbine on dopamine dependent behaviours in rats and mice.
Bende MM; Bapat TR; Balsara JJ; Chandorkar AG
Indian J Physiol Pharmacol; 1990 Jul; 34(3):195-200. PubMed ID: 2286423
[TBL] [Abstract][Full Text] [Related]
19. SCH 23390, a potential benzazepine antipsychotic with unique interactions on dopaminergic systems.
Iorio LC; Barnett A; Leitz FH; Houser VP; Korduba CA
J Pharmacol Exp Ther; 1983 Aug; 226(2):462-8. PubMed ID: 6135795
[TBL] [Abstract][Full Text] [Related]
20. Is it possible to predict the clinical effects of neuroleptics from animal data? Part V: From haloperidol and pipamperone to risperidone.
Janssen PA; Awouters FH
Arzneimittelforschung; 1994 Mar; 44(3):269-77. PubMed ID: 7514873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
